FHIR IG analytics| Package | us.nlm.vsac |
| Resource Type | ValueSet |
| Id | ValueSet-2.16.840.1.113762.1.4.1290.22.json |
| FHIR Version | R4 |
| Source | https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1290.22/expansion |
| URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1290.22 |
| Version | 20250925 |
| Status | active |
| Date | 2025-09-25T01:02:56-04:00 |
| Name | SCAHydroxyureaTreatment |
| Title | SCA hydroxyurea treatment |
| Realm | us |
| Authority | hl7 |
| Description | For MCO reporting using admin data |
| Purpose | (Clinical Focus: hydroxyurea treatment for sickle cell anemia Hb SS or Hb S beta zero thalassemia),(Data Element Scope: RxNorm codes for hydroxyurea treatment for sickle cell anemia),(Inclusion Criteria: RxNorm codes for hydroxyurea treatment),(Exclusion Criteria: none) |
No resources found
| CodeSystem | |
| rxnorm | RxNorm |
No narrative content found in resource
{
"resourceType": "ValueSet",
"id": "2.16.840.1.113762.1.4.1290.22",
"meta": {
"versionId": "5",
"lastUpdated": "2025-09-25T01:02:56.000-04:00",
"profile": [
"http://hl7.org/fhir/StructureDefinition/shareablevalueset",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
]
},
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/valueset-author",
"valueContactDetail": {
"name": "IPRO Author"
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
"valueDate": "2025-09-25"
},
{
"url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
"valueDate": "2025-09-25"
}
],
"url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1290.22",
"identifier": [
{
"system": "urn:ietf:rfc:3986",
"value": "urn:oid:2.16.840.1.113762.1.4.1290.22"
}
],
"version": "20250925",
"name": "SCAHydroxyureaTreatment",
"title": "SCA hydroxyurea treatment",
"status": "active",
"date": "2025-09-25T01:02:56-04:00",
"publisher": "IPRO Steward",
"description": "For MCO reporting using admin data",
"jurisdiction": [
{
"coding": [
{
"system": "urn:iso:std:iso:3166",
"code": "US"
}
]
}
],
"purpose": "(Clinical Focus: hydroxyurea treatment for sickle cell anemia Hb SS or Hb S beta zero thalassemia),(Data Element Scope: RxNorm codes for hydroxyurea treatment for sickle cell anemia),(Inclusion Criteria: RxNorm codes for hydroxyurea treatment),(Exclusion Criteria: none)",
"compose": {
"include": [
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"concept": [
{
"code": "5552",
"display": "hydroxyurea"
}
]
}
]
},
"expansion": {
"identifier": "urn:uuid:80b6bd05-fe48-44d2-87c8-39827de2ed28",
"timestamp": "2025-11-24T16:58:41-05:00",
"total": 1,
"contains": [
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "09022025",
"code": "5552",
"display": "hydroxyurea"
}
]
}
}